Measles - Disease Information Statement (DIS)

1. What is measles?

Measles is a self-limiting childhood viral infection.

  • Measles symptoms include a prodromal (initial) phase of cough, runny nose, eye irritation and fever, followed by a generalized rash on days 4–10 of the illness.1
  • Measles is contagious during the prodromal phase and for 3-4 days after rash onset.1
  • Most measles cases are benign and not reported to public health departments.2
  • Before the measles mass vaccination program was introduced, nearly everyone contracted measles and obtained lifetime immunity by age 15.1
  • In rare situations, measles can cause brain damage and death.3,4

2. What are the risks?

In the modern era, it is rare to suffer permanent disability or death from measles in the United States.

Between 1900 and 1963, the mortality rate of measles dropped from 13.3 per 100,000 to 0.2 per 100,000 in the population, due to advancements in living conditions, nutrition, and health care—a 98% decline (Fig. 1).2,5

Malnutrition, especially vitamin A deficiency, is a primary cause of about 90,000 measles deaths annually in underdeveloped nations.6 In the U.S. and other developed countries, 75–92% of hospitalized measles cases are low in vitamin A.7,8

Research studies and national tracking of measles have documented the following:

  • 1 in 10,000 or 0.01% of measles cases are fatal.3
  • 3 to 3.5 in 10,000 or 0.03–0.035% of measles cases result in seizure.9
  • 1 in 20,000 or 0.005% of measles cases result in measles encephalitis.4
  • 1 in 80,000 or 0.00125% of cases result in permanent disability from measles encephalitis.4
  • 7 in 1,000 or 0.7% of cases are hospitalized.10

Figure 1: Measles death declined 98% from 1900 to 1963, before the measles vaccine was introduced.

3. What treatments are available for measles?

Because measles resolves on its own in almost all cases, usually only supportive treatment is necessary. As such, treatment options include the following:

  • Rest
  • Hydration
  • High-dose vitamin A11
  • Immunoglobulin (available for immunocompromised patients, such as those on chemotherapy)12

4. Are there any benefits from getting measles?

There are studies that suggest a link between naturally acquired measles infection and a reduced risk of Hodgkin’s and non-Hodgkin’s lymphomas, as well as a reduced risk of atopic diseases such as hay fever, eczema and asthma.13-17 In addition, measles infections are associated with a lower risk of mortality from cardiovascular disease in adulthood.18 Moreover, infants born to mothers who have had naturally acquired measles are protected from measles via maternal immunity longer than infants born to vaccinated mothers.19

5. What about the vaccine for measles?

The measles vaccine was introduced in the U.S. in 1963 and is now only available as a component of the measles, mumps, and rubella (MMR) vaccine. It has significantly reduced the incidence of measles; however, the vaccine is not capable of preventing all cases of measles, as failures have been reported.20 The manufacturer’s package insert contains information about vaccine ingredients, adverse reactions, and vaccine evaluations. For example, “M-M-R II vaccine has not been evaluated for carcinogenic or mutagenic potential, or potential to impair fertility.”21  Furthermore, the risk of permanent injury and death from the MMR vaccine has not been proven to be less than that of measles (Fig. 2).22, 23

Figure 2: This graph shows the measles death rate before the vaccine was introduced, when measles was a common childhood viral infection, and compares it to the leading causes of death in children under age 10 today. Hence, in the pre-vaccine era, the measles death rate per 100,000 was 0.9 for children under age 10. In 2015, the death rate per 100,000 for homicide was 1.3, followed by cancer (2.0), SIDS (3.9), unintentional injury (8.2), and congenital anomalies (13.6). The rate of death or permanent injury from the MMR vaccine is unknown because the research studies available are not able to measure it with sufficient accuracy.22, 23


  1. Centers for Disease Control. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Hamborsky J, Kroger A, Wolfe S, editors. Washington D.C.: Public Health Foundation; 2015. 209-15.
  2. Between 1959 and 1962, annually there were about 4 million cases, of which 440,000 (11%) were reported.
    • Centers for Disease Control. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Hamborsky J, Kroger A, Wolfe S, editors. Washington D.C.: Public Health Foundation; 2015. Appendix E3.
    • Centers for Disease Control. Measles prevention: recommendations of the Immunization Practices Advisory Committee (ACIP). Morbidity and Mortality Weekly Report. 1989; 38(S-9):1.
  3. Between 1959 and 1962, annually there were 400 measles deaths out of 4 million cases, about 1 in 10,000 cases.
    • Same sources as reference 2.

    • Langmuir AD, Henderson DA, Serfling RE, Sherman IL. The importance of measles as a health problem. Am J Public Health Nations Health. 1962 Feb;52(2)Suppl:1-4.

  4. Measles surveillance in the 1980s and 1990s showed that there are half as many cases of measles encephalitis as there are measles deaths, 1 in 20,000 cases (50% of 1 in 10,000 cases of death). Of these cases, 25% (1 in 80,000 cases) result in residual neurological injury.
    • Same sources as references 1 and 3.
  5. Grove RD; Hetzel AM; U.S. Department of Health, Education, and Welfare. Vital statistic rates in the United States 1940-1960. Washington D.C.: U.S. Government Printing Office;1968. 559-603.
  6. The measles case-fatality rate in underdeveloped nations, where vitamin A deficiency is prevalent, is about 3–6% of reported cases, 30 to 60 times higher than in developed countries.
  7. Butler JC, Havens PL, Sowell AL, Huff DL, Peterson DE, Day SE, Chusid MJ, Bennin RA, Circo R, Davis JP. Measles severity and serum retinol (vitamin A) concentration among children in the United States. Pediatrics. 1993 Jun;91(6):1177-81.
  8. Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med. 1990 July;323(3):160-4.
  9. Measles surveillance in the 1980s and 1990s showed that there are 3 to 3.5 times more measles seizures than measles deaths (3 to 3.5 per 10,000 cases).
    • Same sources as references 1 and 3.
  10. Measles surveillance in the 1980s and 1990s showed that there are about 70 times more measles hospitalizations than measles deaths (7 per 1,000 cases).
    • Same sources as reference 3.
    • Centers for Disease Control. Current trends measles—United States, 1989 and first 20 weeks 1990, June 1990. MMWR. 1990;39(21):353-5,361-3.
  11. Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis. 2004 May 1;189 Suppl 1: S4-16.
  12. California Department of Public Health. Measles investigation quicksheet. May 2011.
  13. Alexander FE, Jarrett RF, Lawrence D, Armstrong AA, Freeland J, Gokhale DA, Kane E, Taylor GM, Wright DH, Cartwright RA. Risk factors for Hodgkin’s disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer. 2000 Mar;82(5):1117-21.
  14. Glaser SL, Keegan TH, Clarke CA, Trinh M, Dorfman RF, Mann RB, DiGiuseppe JA, Ambinder RF. Exposure to childhood infections and risk of Epstein-Barr virus—defined Hodgkin’s lymphoma in women. Int J Cancer. 2005 Jul 1;115(4):599-605.
  15. Montella M, Maso LD, Crispo A, Talamini R, Bidoli E, Grimaldi M, Giudice A, Pinto A, Franceschi S. Do childhood diseases affect NHL and HL risk? A case-control study from northern and southern Italy. Leuk Res. 2006 Aug;30(8):917-22.
  16. Shaheenet SO, Aaby P, Hall AJ, Barker DJ, Heyes CB, Shiell AW, Goudiaby A. Measles and atopy in Guinea-Bissau. Lancet. 1996 Jun 29;347:1792-6.
  17. Rosenlund H, Bergström A, Alm JS, Swartz J, Scheynius A, van Hage M, Johansen K, Brunekreef B, von Mutius E, Ege MJ, Riedler J, Braun-Fahrländer C, Waser M, Pershagen G; PARSIFAL Study Group. Allergic disease and atopic sensitization in children in relation to measles vaccination and measles infection. Pediatrics. 2009 Mar;123(3):771-8.
  18. Kubota Y, Iso H, Tamakoshi A, JACC Study Group. Association of measles and mumps with cardiovascular disease. The Japan Collaborative Cohort (JACC) study. Atherosclerosis. 2015 August;241(2):682-6.
  19. Waaijenborg S, Hahné SJ, Mollema L, Smits GP, Berbers GA, van der Klis FR, de Melker HE, Wallinga J. Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage. J Infect Dis. 2013 Jul;208(1):10-6.
  20. Poland GA, Jacobson RM. The re-emergence of measles in developed countries: time to develop the next-generation measles vaccines? Vaccine. 2012 Jan 5;30(2):103-4.
  21. U.S. Food and Drug Administration: M-M-R II (measles, mumps, and rubella virus vaccine live). Whitehouse Station: Merck & Co., Inc.; c1971 [cited 2017 June 21].
  22. Physicians for Informed Consent. Measles – vaccine risk statement (VRS). Dec 2017.
  23. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database of Syst Rev. 2012 Feb 15;(2).
  24. 10 leading causes of death by age group, United States—2015. Atlanta: Centers for Disease Control and Prevention [cited 2017 June 21].
  25. U.S. Department of Health, Education, and Welfare. Vital statistics of the United States 1962, volume 2—mortality, part A. Washington D.C.: U.S. Government Printing Office; 1964. 94.

These statements are intended for informational purposes only and should not be construed as personal medical advice.

© 2018 Physicians for Informed Consent, an independent 501(c)(3) nonprofit educational organization. Updated Dec 2017.